Advertisement
JNJ vs MRK
Which Stock Would AI Choose? Johnson & Johnson (JNJ) vs. Merck & Co. (MRK) Stock Comparison
Key Takeaways
- JNJ has delivered stronger year-to-date performance compared to MRK amid broader market conditions.
- Johnson & Johnson benefits from a diversified business model spanning pharmaceuticals and medical devices, providing relative stability.
- Merck & Co. maintains strong positioning in oncology, though its performance has shown more variability in recent market activity.
- Both companies reported solid first-quarter 2026 results, with JNJ raising full-year guidance following its earnings release.
- Market capitalization favors JNJ significantly over MRK, reflecting differences in scale and diversification.
- Recent weeks have highlighted contrasting momentum, with JNJ exhibiting greater consistency in upward trends.
Introduction
Johnson & Johnson (JNJ) and Merck & Co. (MRK) represent two leading pharmaceutical companies with substantial market influence. This comparison examines their relative performance, business profiles, and positioning within the healthcare sector during recent market activity. Investors and traders focused on large-cap healthcare equities, dividend stability, or sector rotation strategies may find this analysis relevant for assessing portfolio allocation between diversified conglomerates and specialized innovators. The review emphasizes verifiable developments and observable metrics without forward projections.
JNJ Overview and Recent Performance
Johnson & Johnson operates as a diversified healthcare company with segments in Innovative Medicine and MedTech. In recent weeks, the stock has shown resilience, trading near levels around $263 following periods of volatility and reaching an all-time closing high near $267 in early July 2026. Year-to-date returns have exceeded broader market benchmarks. First-quarter 2026 results featured reported sales growth of 9.9% to $24.1 billion and a raised full-year outlook, supporting positive sentiment. Factors influencing performance include pipeline advancements and MedTech contributions, which have helped maintain stability amid sector fluctuations.
MRK Overview and Recent Performance
Merck & Co. focuses primarily on pharmaceuticals, with notable strength in oncology products. In recent weeks, shares have traded in the $126 range, near a 52-week high of approximately $130 reached in late June 2026. Year-to-date performance has been positive but trailed that of peers in the sector. Recent market activity reflects ongoing interest in its oncology portfolio, though the stock has experienced sharper intraday movements compared to broader healthcare averages. First-quarter results contributed to sustained investor attention, with emphasis on revenue from key therapeutic areas driving relative positioning.
Trending AI Robots
Tickeron’s Trending AI Robots page curates select AI trading bots from hundreds available that trade thousands of different tickers. Only those demonstrating the strongest alignment with prevailing market conditions receive placement in this section. Available bots span a wide range of trading styles, strategies, timeframes, and performance statistics, with many reporting win rates between 60% and 80% alongside varying profit factors and drawdown metrics across diverse ticker sets. This curated selection provides traders with data-driven options tailored to current environments. Explore the full range on the Trending AI Robots page for additional details.
Head-to-Head Comparison
Johnson & Johnson and Merck & Co. differ markedly in business models: JNJ offers diversification across pharmaceuticals and medical devices, reducing exposure to single-product risks, while MRK concentrates on high-growth areas such as oncology. Recent momentum has favored JNJ with stronger year-to-date gains and guidance upgrades following earnings. Risk factors include JNJ’s larger scale potentially limiting agility versus MRK’s greater sensitivity to clinical or regulatory developments in its focused pipeline. Sector exposure remains healthcare-centric for both, though JNJ’s MedTech component provides additional ballast. Market sentiment in recent activity has reflected greater consistency for the diversified player amid broader volatility.
Tickeron AI Verdict
Tickeron’s AI models currently indicate a probabilistic preference for JNJ based on observable trend consistency, post-earnings momentum, diversified stability, and relative outperformance in recent market activity. Factors such as raised guidance and balanced segment contributions support this positioning over MRK’s more variable trajectory. MRK retains potential for rebounds tied to oncology catalysts. This assessment draws from measurable data points rather than guarantees.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JNJ is a StrongBuy and MRK is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
JNJ’s FA Score shows that 3 FA rating(s) are green whileMRK’s FA Score has 3 green FA rating(s).
- JNJ’s FA Score: 3 green, 2 red.
- MRK’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
JNJ’s TA Score shows that 6 TA indicator(s) are bullish while MRK’s TA Score has 5 bullish TA indicator(s).
- JNJ’s TA Score: 6 bullish, 4 bearish.
- MRK’s TA Score: 5 bullish, 4 bearish.
Price Growth
JNJ (@Pharmaceuticals: Major) experienced а +3.71% price change this week, while MRK (@Pharmaceuticals: Major) price change was +0.49% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.70%. For the same industry, the average monthly price growth was +15.93%, and the average quarterly price growth was +7.43%.
Reported Earning Dates
JNJ is expected to report earnings on Jul 15, 2026.
MRK is expected to report earnings on Aug 04, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-1.70% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| JNJ | MRK | JNJ / MRK | |
| Capitalization | 634B | 311B | 204% |
| EBITDA | 33.7B | 19.4B | 174% |
| Gain YTD | 28.690 | 21.448 | 134% |
| P/E Ratio | 30.52 | 35.49 | 86% |
| Revenue | 96.4B | 65.8B | 147% |
| Total Cash | 22.1B | N/A | - |
| Total Debt | 55B | 49.1B | 112% |
JNJ | MRK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 29 | 22 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 40 Fair valued | 15 Undervalued | |
PROFIT vs RISK RATING 1..100 | 5 | 42 | |
SMR RATING 1..100 | 36 | 47 | |
PRICE GROWTH RATING 1..100 | 7 | 17 | |
P/E GROWTH RATING 1..100 | 11 | 5 | |
SEASONALITY SCORE 1..100 | 75 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MRK's Valuation (15) in the Pharmaceuticals Major industry is in the same range as JNJ (40). This means that MRK’s stock grew similarly to JNJ’s over the last 12 months.
JNJ's Profit vs Risk Rating (5) in the Pharmaceuticals Major industry is somewhat better than the same rating for MRK (42). This means that JNJ’s stock grew somewhat faster than MRK’s over the last 12 months.
JNJ's SMR Rating (36) in the Pharmaceuticals Major industry is in the same range as MRK (47). This means that JNJ’s stock grew similarly to MRK’s over the last 12 months.
JNJ's Price Growth Rating (7) in the Pharmaceuticals Major industry is in the same range as MRK (17). This means that JNJ’s stock grew similarly to MRK’s over the last 12 months.
MRK's P/E Growth Rating (5) in the Pharmaceuticals Major industry is in the same range as JNJ (11). This means that MRK’s stock grew similarly to JNJ’s over the last 12 months.
| JNJ | MRK | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 24% | 1 day ago 49% |
| Stochastic ODDS (%) | 1 day ago 48% | 1 day ago 66% |
| Momentum ODDS (%) | 1 day ago 42% | 1 day ago 54% |
| MACD ODDS (%) | 1 day ago 36% | 1 day ago 48% |
| TrendWeek ODDS (%) | 1 day ago 44% | 1 day ago 49% |
| TrendMonth ODDS (%) | 1 day ago 46% | 1 day ago 54% |
| Advances ODDS (%) | 8 days ago 44% | 11 days ago 54% |
| Declines ODDS (%) | 22 days ago 42% | 9 days ago 51% |
| BollingerBands ODDS (%) | 1 day ago 32% | 1 day ago 48% |
| Aroon ODDS (%) | 1 day ago 45% | 1 day ago 62% |
Advertisement